Comparison of Length of Stay of Severe and Critical COVID-19 Patients with Diabetes Mellitus, Hypertension, and Other Comorbidities
DOI:
https://doi.org/10.36497/jri.v45i1.591Keywords:
comorbidities, COVID-19, diabetes mellitus, hypertension, length of stayAbstract
Background: Coronavirus Disease-19 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). In 2020, a disease known as COVID-19 became a global pandemic. This disease can spread through the air or mucosal contact with the body. The impact of COVID-19 varies greatly from person to person and depends on various factors, including any pre-existing health conditions. This study aimed to determine the hospitalization period for severe and critical COVID-19 patients with comorbidities such as diabetes mellitus, hypertension, obesity, heart failure, stroke, pregnancy, coronary artery disease, and asthma in the Intensive Care Unit at RSUD Dr. Saiful Anwar in Malang.
Methods: This study used an observational analysis method by taking secondary data from medical records and out-of-hospital data of patients admitted to the Intensive Care Unit. The data that has been collected is carried out by a normality test using the Saphiro-Wilk test then the Kruskal-Wallis test and the Dunn test as a follow-up test.
Results: The study was dominated by subjects less than 60 years of age, male, and most had comorbidities. It was found that only in death outcome group has a significance value of P<0.05, with the longest hospital stays in patients without comorbidities and patients with diabetes mellitus only (ICU Median=7.5 days), while the shortest length of stay was obtained in patients with comorbidities other than diabetes and hypertension (ICU Median=3.5 days).
Conclusion: The presence of multiple comorbidities in patients is associated with greater severity of illness, resulting in longer hospital stays among those who are discharged. Conversely, patients who experience death outcomes tend to have shorter lengths of stay in the hospital.
Downloads
References
1. World Health Organization. WHO COVID-19 dashboard [Internet]. 2022 [cited 2022 Dec 28]. Available from: https://data.who.int/dashboards/covid19/cases?n=c
2. Satuan Tugas Penanganan COVID-19 Indonesia. Peta sebaran COVID-19 [Internet]. 2022 [cited 2022 Dec 28]. Available from: https://covid19.go.id/peta-sebaran
3. World Health Organization. Coronavirus disease (COVID-19): How is it transmitted? [Internet]. 2021 [cited 2021 Aug 19]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted
4. Kementrian Kesehatan Republik Indonesia (Kemenkes RI). Pedoman pencegahan dan pengendalian coronavirus disease (Covid-19) revisi ke-5. Jakarta; 2020. p. 1–214.
5. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(5):1133–42.
6. Anderson MR, Bach PB, Baldwin MR. Hospital length of stay for patients with severe COVID-19: Implications for remdesivir’s value. Pharmacoecon Open. 2021;5(1):129–31.
7. Boehmer TK, DeVies J, Caruso E, van Santen KL, Tang S, Black CL, et al. Changing age distribution of the COVID-19 pandemic — United States, May–August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(39):1404–9.
8. Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The association between presence of comorbidities and COVID-19 severity: A systematic review and meta-analysis. Cerebrovascular Diseases. 2021;50(2):132–40.
9. Al-Salameh A, Lanoix JP, Bennis Y, Andrejak C, Brochot E, Deschasse G, et al. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. Diabetes Metab Res Rev. 2021;37(3):e3388.
10. Wu S, Xue L, Legido-Quigley H, Khan M, Wu H, Peng X, et al. Understanding factors influencing the length of hospital stay among non-severe COVID-19 patients: A retrospective cohort study in a Fangcang shelter hospital. PLoS One. 2020;15(10):1–14.
11. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–55.
12. Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol. 2021;57:14–21.
13. Jang SY, Seon JY, Yoon SJ, Park SY, Lee SH, Oh IH. Comorbidities and factors determining medical expenses and length of stay for admitted covid-19 patients in Korea. Risk Manag Healthc Policy. 2021;14:2021–33.
14. Sanyaolu A, Okorie C, Marinkovic A, Patidar R. Comorbilidad y su impacto en pacientes con COVID-19. SN Compr Clin Med. 2020;2(19(Supl)):e3389.
15. Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. The Journal of infection. 2020;81:e95–7.
16. Dandona P, Ghanim H. Diabetes, obesity, covid-19, insulin, and other antidiabetes drugs. Diabetes Care. 2021;44(9):1929–33.
17. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):303–10.
18. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Comorbid diabetes mellitus was associated with poorer prognosis in patients with COVID-19: A retrospective cohort study. medRxiv. 2020;
19. Chen FJ, Li FR, Zheng JZ, Zhou R, Liu HM, Wu KY, et al. Factors associated with duration of hospital stay and complications in patients with covid-19. J Public Health Emerg. 2021;5:6.
20. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: A multicenter retrospective observational study. Hypertens Res. 2020;43(8):824–31.
21. Salmen T, Pietroșel VA, Mihai BM, Bica IC, Teodorescu C, Păunescu H, et al. Non-insulin novel antidiabetic drugs mechanisms in the pathogenesis of COVID-19. Biomedicines. 2022;10(10):2624.
22. Sun B, Huang S, Zhou J. Perspectives of antidiabetic drugs in diabetes with coronavirus infections. Front Pharmacol. 2021;11:592439.
23. Dimnjaković J, Buble T, Ivanko P, Pristaš I, Brborović O, Brborović H. Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy. Sci Rep. 2024;14(1):7227.
24. Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A. Potential benefits and harms of novel antidiabetic drugs during COVID-19 crisis. Int J Environ Res Public Health. 2020;17(10):3664.
25. Braude P, Carter B, Short R, Vilches-Moraga A, Verduri A, Pearce L, et al. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc. 2020;31:100660.
26. Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C. Hypertension and COVID-19: Ongoing controversies. Front Cardiovasc Med. 2021;8:639222.
27. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: A systematic review and meta-analysis. J Med Virol. 2021;93(1):257–61.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Yani Jane Sugiri, Arie Zainul Fatoni, Theresia Daniella Rosita
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
